These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 2288502)

  • 21. A population-based treat-to-target pharmacoeconomic analysis of HMG-CoA reductase inhibitors in hypercholesterolemia.
    Hilleman DE; Phillips JO; Mohiuddin SM; Ryschon KL; Pedersen CA
    Clin Ther; 1999 Mar; 21(3):536-62. PubMed ID: 10321422
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of lovastatin therapy in adolescent girls with heterozygous familial hypercholesterolemia.
    Clauss SB; Holmes KW; Hopkins P; Stein E; Cho M; Tate A; Johnson-Levonas AO; Kwiterovich PO
    Pediatrics; 2005 Sep; 116(3):682-8. PubMed ID: 16140708
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lovastatin: an HMG-CoA reductase inhibitor for lowering cholesterol.
    Frishman WH; Rapier RC
    Med Clin North Am; 1989 Mar; 73(2):437-48. PubMed ID: 2645482
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of heterozygous familial hypercholesterolemia with lipid-lowering drugs.
    Illingworth DR; Bacon S
    Arteriosclerosis; 1989; 9(1 Suppl):I121-34. PubMed ID: 2492189
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cholesterol homeostasis in mononuclear leukocytes from patients with familial hypercholesterolemia treated with lovastatin.
    Hagemenas FC; Illingworth DR
    Arteriosclerosis; 1989; 9(3):355-61. PubMed ID: 2719596
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Which statin is most efficient for the treatment of hypercholesterolemia? A cost-effectiveness analysis.
    Cobos A; Jovell AJ; García-Altés A; García-Closas R; Serra-Majem L
    Clin Ther; 1999 Nov; 21(11):1924-36. PubMed ID: 10890264
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term efficacy and safety of rosuvastatin 40 mg in patients with severe hypercholesterolemia.
    Stein EA; Amerena J; Ballantyne CM; Brice E; Farnier M; Guthrie RM; Harats D; Ma PT; Le Maulf F; Melezínková H; Gold A; Sager P
    Am J Cardiol; 2007 Nov; 100(9):1387-96. PubMed ID: 17950795
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Simvastatin (MK-733), a new HMG-CoA reductase inhibitor, in the treatment of hypercholesterolemia in elderly patients with atherosclerosis].
    Giannini SD; de Góes JM; Dereviack BE; Machado C; Forti N; Diament J
    Arq Bras Cardiol; 1990 Jun; 54(6):407-14. PubMed ID: 2288531
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Simvastatin therapy for hypercholesterolaemia in patients with coronary heart disease.
    French JK; White HD; Greaves SC
    N Z Med J; 1990 Feb; 103(883):41-3. PubMed ID: 2304688
    [TBL] [Abstract][Full Text] [Related]  

  • 30. HMG-CoA reductase inhibitors for hypercholesterolemia.
    N Engl J Med; 1988 Nov; 319(18):1222-3. PubMed ID: 3173461
    [No Abstract]   [Full Text] [Related]  

  • 31. Inhibition of cholesterol absorption by HMG-CoA reductase inhibitor.
    Miettinen TA
    Eur J Clin Pharmacol; 1991; 40 Suppl 1():S19-21. PubMed ID: 1904356
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Effect of cholesterol reducing therapy with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor on secondary prevention after myocardial infarction in Japanese patients].
    Tachibana E; Watanabe I; Nagao K; Kanmatsuse K
    J Cardiol; 2000 Apr; 35(4):277-85. PubMed ID: 10791271
    [TBL] [Abstract][Full Text] [Related]  

  • 33. ["The lower LDL cholesterol levels, the better" still valid. Negative/neutral conclusions of three studies on statins do not change the clinical practice].
    Olsson AG; Nilsson PM
    Lakartidningen; 2009 Mar 18-24; 106(12):854-7. PubMed ID: 19452786
    [No Abstract]   [Full Text] [Related]  

  • 34. Low density lipoprotein density and composition in hypercholesterolaemic men treated with HMG CoA reductase inhibitors and gemfibrozil.
    Tilly-Kiesi M; Tikkanen MJ
    J Intern Med; 1991 May; 229(5):427-34. PubMed ID: 2040869
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The synergistic hypocholesterolemic activity of the potent cholesterol absorption inhibitor, ezetimibe, in combination with 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors in dogs.
    Davis HR; Pula KK; Alton KB; Burrier RE; Watkins RW
    Metabolism; 2001 Oct; 50(10):1234-41. PubMed ID: 11586500
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [HMG-CoA reductase inhibitors].
    Yamamoto A
    Nihon Rinsho; 2001 Mar; 59 Suppl 3():578-86. PubMed ID: 11347135
    [No Abstract]   [Full Text] [Related]  

  • 37. Effect of lovastatin on hypercholesterolemia in chronic renal failure.
    Subang MC; Stewart-Phillips JL; Gagnon RF
    Adv Perit Dial; 1992; 8():381-4. PubMed ID: 1361828
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of HMG-CoA reductase inhibitors on red blood cell membrane lipids and haemorheological parameters, in patients affected by familial hypercholesterolemia.
    Martinez M; Vaya A; Marti R; Gil L; Lluch I; Carmena R; Aznar J
    Haemostasis; 1996 Oct; 26 Suppl 4():171-6. PubMed ID: 8979121
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Influence of the HMG-CoA-reductase inhibitor lovastatin on cholesterol saturation index and nucleation time of duodenal bile.
    Nitsche R; Schlage J; Ramin V; Kirchhoff S; Fölsch UR; Creutzfeldt C; Creutzfeldt W
    Z Gastroenterol; 1991 May; 29(5):242-5. PubMed ID: 1950033
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Drug therapy of hypercholesterolemia.
    Illingworth DR
    Clin Chem; 1988; 34(8B):B123-32. PubMed ID: 3042195
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.